Core Insights - Opus Genetics, Inc. (NASDAQ:IRD) is recognized as one of the 11 fastest growing penny stocks to consider for investment [1] - BTIG has raised the price target for Opus Genetics from $7 to $12 while maintaining a Buy rating, indicating a positive outlook on the company's growth potential [2][8] - The company is focused on developing therapies for inherited retinal diseases, with ongoing clinical trials showing promising results [5] Clinical Developments - New clinical data from the Phase 1/2 study of OPGx-BEST1 gene therapy was presented, showing that the therapy was well tolerated with no adverse events reported [3] - The sentinel patient demonstrated a 12-letter improvement in Best Corrected Visual Acuity and a 23% reduction in central subfield thickness, indicating structural improvements [3] - Recruitment for the OPGx-BEST1 study is ongoing at two U.S. clinical sites, with plans to expand to additional locations [4] Regulatory Progress - The U.S. FDA has accepted the supplemental New Drug Application for phentolamine ophthalmic solution 0.75% for presbyopia treatment, with a PDUFA goal date set for October 17, 2026 [4]
BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating